Why Amazon, Starbucks and Three Other Stocks Are Trending Today

SAGE Surges on Study Results

SAGE Therapeutics Inc (NASDAQ:SAGE) is 34% higher today after a Phase 2 study showed that the company’s product candidate SAGE-547 had met the primary endpoint in terms of statistically reducing postpartum depression symptoms compared to placebo. The study also showed that there were no serious adverse events and that the drug was well tolerated. SAGE will continue the development of SAGE-547 by expanding its Phase 2 clinical program to determine optimal dosing of the drug for the potential treatment of postpartum depression. The number of funds from our database with holdings in SAGE Therapeutics Inc (NASDAQ:SAGE) fell by two quarter-over-quarter to 21 at the end of March.

M&A Rumors Between Xerox and RR Donnelley

Xerox Corp (NYSE:XRX) and RR Donnelley & Sons Co (NASDAQ:RRD) have gained over 2% each today after a Bloomberg report stated that Xerox is in negotiations to acquire R. R. Donnelley. Although the talks are early stage and there is no guarantee of a deal, the tie-up between the two companies could potentially be done before Xerox splits into two companies by the end of the year. R.R. Donnelley is the owner of the Edgar financial reporting service. Among the funds we track, 29 funds had a bullish position in Xerox Corp (NYSE:XRX) at the end of March, up by four funds from the previous quarter. Meanwhile, 22 investors were long RR Donnelley & Sons Co (NASDAQ:RRD) at the end of March, down by one from the end of the fourth quarter.

Disclosure: None